Ö±³¦¼²²¡/Íâ¿ÆÊÖÊõ,rectal diseases/surgeryÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÎÞË®ÒÒ´¼×¢Éä,percutaneous ethanol injectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÆêѪ½¬,umbilical cord plasmaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¸Îϸ°ûÁö,HepatomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÄÒÐÔÁܰ͹ÜÁö,cystic lymphangiomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÅèÇ»×ÔÖ÷Éñ¾´Ô,Pelvic autonomic nerve Plexus(PANP)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¾Æ¾«×¢Éä,Percutaneous ethanol injectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
δ·Ö»¯°©,Undifferentiated carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ê®¶þÖ¸³¦Ö×Áö/Íâ¿ÆÑ§,Duodenal Neoplasms/surgÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ê®¶þÖ¸³¦Ö×Áö/Õï¶Ï,Duodenal Neoplasms/diagÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
µÍ·Ö»¯,Poorly differentiatedÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¾Ö²¿Ö×Áö¸´·¢,Local neoplasm recurrenceÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
½áÖ±³¦Ö×Áö/Á÷Ðв¡Ñ§,colorectal neoplasms/epidemiologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ϸ°û·¦Ñõ,Cell hypoxiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Eca109ϸ°ûϵ,Eca109 cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¾ÛÏÙÜÕ¶þÁ×ËáºËÌǾۺÏø-1,poly(ADP-ribose) polymerase-1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ê®¶þÖ¸³¦°©,Duodenal carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
DNAÖÜÆÚ,DNA cycleÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
θµ×êÚÃŰ©,gastrocardiac carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÈýÆÚɨÃè,Tri-phase scanningÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶ñÐÔ¹£×è,Malignant obstructionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
θÖ×Áö/·ÅÉäÁÆ·¨,stomach neoplasms/radiotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
BRCA2µ°°×,BRCA2 proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÍßÌØºø¸¹,Vater's ampullaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÓÕ²¶ÊÜÌå3,Decoy receptor 3Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
hOGG1»ùÒò,hOGG1 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ɽ²è,CamelliaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÁÙ´²²¡ÀíÒòËØ,clinicopathologic factorsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
×ªÒÆ¹æÂÉ,Metastatic ruleÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×ÁöÒ©Ãô,Anticancer sensitivityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
TECIA·¨,TECIA assayÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÄÚÔ൰°×,Visceral proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÈÈÐݿ˵°°×70¶àëĸ´ºÏÎï,Heat shock protein 70 peptide complexÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¸Î¶ñÐÔÖ×Áö,Liver malignant tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÉÏÏû»¯µÀ°©,upper digestive tract cancerÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
³¦Ö×Áö/²¡Àíѧ,Intestinal neoplasms/pathologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÉÏ賦µÀ,Upper gastrointestinal tractÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Survivin¿¹Ô,Survivin antigenÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Musashi-1»ùÒò,Musashi-1 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
°±»ùͪÎìËá,Aminolevulinic acidÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
»ùÒò±í´ïоƬ,Gene expression chipsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
BGC-823ϸ°ûϵ,BGC-823 cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Eca-109ϸ°ûϵ,Eca-109 cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÔçÆÚÖ±³¦°©,Early rectal cancerÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
À»Î²Ö×Áö,appendiceal neoplasmsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
³¬·Ö¸î·ÅÁÆ,Hyperfractionated radiotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ʵÐÔ-¼ÙÈéÍ·×´Áö,solid-pseudopapillary tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ô·¢ÐÔ¸ÎÖ×Áö,Primary liver cancerÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÄÒÐÔÖ×Áö,cystic tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¸ÎÖ×Áö/ÖÐÒ©ÁÆ·¨,LIVER NEOPLASMS/TCD therapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÒÅ´«ÐÔ·ÇÏ¢ÈâÐԴ󳦰©,hereditary non-polyposis colorectal cancerÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÐØÎ¸,intrathoracic stomachÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ó¸òܶ¾ËØ,toad toxicationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·ÅÉäÁ£×Ó,Radioactive seedsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÏµÄ¤×ªÒÆ,Mesorectal metastasisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
µ¨µÀ×èÈû,Biliary obstructionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Éú³¤ÒÖËØÊÜÌåÑÇÐÍ,somatostatin receptor subtypeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ϸ°ûÔöÖ³ÒÖÖÆ,inhibition of cell proliferationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¾â³Ý×´ÏÙÁö,Serrated adenomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ѪÇåÍÙÒºËá,sialic acidÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÄÉÃ×Ì¿»ìÐü×¢ÉäÒº,carbon nanoparticles suspension injectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
´ó¸Î°©,large hepatocellular carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
SGC7901ϸ°ûϵ,SGC7901 cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ëÄ»ù¸¬°±õ£Ò칹ø,Peptidylprolyl isomeraseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
С·Ö×ÓÒÖÖÆ¼Á,small-molecule inhibitorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Sonichedgehog,Sonic hedgehogÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Éñ¾ÏµÍ³/²¡Àíѧ,nervous system/pathologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
BGC823ϸ°û,BGC823 cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
hTERTmRNA,hTERT mRNAÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
΢СȾɫÌåά³Öµ°°×2,minichromosome maintenance protein 2Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÒÅ´«Ò׸Ð,genetic susceptibilityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
P27µ°°×ÖÊ,P27 proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶¹¸ù¹Üʳͨ¿Ú·þÒº,Dougenguanshitong oral liquidÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÈËÔ·¢ÐԸΰ©,Hepatocellular carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
»ùÖʽðÊôµ°°×ø-11,matrix metalloproteinase-11Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
θ°©×ªÒÆ,gastric cancer metastasisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶¾ËØA,toxin AÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
MSH2»ùÒò,MSH2 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
θÖ×Áö/´úл,stomach neoplasms/metabolismÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÐØÏÙà×ऺϳÉø,thymidylate synthaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
SW620ϸ°û,SW620 cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
賦Ö×Áö/Õï¶Ï,Gastrointestinal Neoplasms/diagÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Í»±äÐÍp53»ùÒò,mutation p53 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
EPÊÜÌå,EP receptorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ѫ¹ÜÇÖ·¸,Vascular invasionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
îÆ·ÅÉäÐÔÍ¬Î»ËØ,Yttrium radioisotopesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
°©Ö¢»ùÒò×é½âÆÊ¼Æ»®,Cancer Genome Anatomy ProjectÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶¯ÂöÆÚ,arterial phaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
½á³¦¸Ø¹ÜÎǺÏÊõ,coloanal anastomosisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
´Å¹²ÕñÀ©É¢¼ÓȨ³ÉÏñ,diffusion-weighted MR imagingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
PNP/Mep-dRϵͳ,PNP/Mep-dR suicide gene systemÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
PF·½°¸,PF regimenÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
½á³¦°©Ï¸°ûÖê,Colon cancer cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
9-˳ά¼×Ëá,9-cis-retinoic acidÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Cyclin Eµ°°×,Cyclin E proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
hMLH1µ°°×,hMLH1 proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
CDX2µ°°×,CDX2 proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ô·¢¸Î°©,Primary liver cancerÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Áܰ͹ܽþÈó,Lymphatic vessel invasionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ô·¢ÐÔС³¦Ö×Áö,primary small intestinal tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«

|